Common and less common adverse effects of antihypertensives: a general practitioner's perspective

Trinder, Y.
April 2012
South African Family Practice;Apr/May2012, Vol. 54 Issue 2, pS31
Academic Journal
The article explores the adverse effects associated with antihypertensive drugs. Hypotension due to overtreatment is the most universal adverse effect of antihypertensives. Side effects associated with thiazide diuretics are hypokalaemia, gout and hyponatraemia. It notes that angiontensin-receptor blockers and angiotensin converting enzyme inhibitors have similar side-effect profiles. Peripheral oedema, particularly in women, is the most common side effect of calcium-channel blockers.


Related Articles

  • antihypertensive drugs. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p57 

    An encyclopedia entry for "antihypertensive drugs" is presented. They refer to a group of drugs used in the treatment of hypertension to prevent complications such as stroke, heart failure, myocardial infarction and kidney damage. These drugs, such as ACE inhibitors and angiotensin-II...

  • A Comparison of Two Multiple-Characteristic Decision-Making Models for the Comparison of Antihypertensive Drug Classes: Simple Additive Weighting (SAW) and Technique for Order Preference by Similarity to an Ideal Solution (TOPSIS). Van Wijk, Boris L. G.; Klungel, Olaf H.; Heerdink, Eibert R.; de Boer, Anthonius // American Journal of Cardiovascular Drugs;2006, Vol. 6 Issue 4, p251 

    BACKGROUND: Multiple-characteristics decision-making (MCDM) models can be used to calculate a score, based on a set of characteristics, for a number of alternative drugs or drug classes to allow comparison between them and thus enhance evidence-based pharmacotherapy. OBJECTIVE: To compare two...

  • Lercanidipine/nicardipine/nitrendipine.  // Reactions Weekly;10/19/2013, Issue 1474, p27 

    The article presents a case study of a 36-year-old woman who developed a bullous eruption while treating with lercanidipine and nicardipine for hypertension.

  • Azilsartan Improves Glycemic Status and Reduces Kidney Damage in Zucker Diabetic Fatty Rats. Khan, Md. Abdul Hye; Neckář, Jan; Haines, Jasmine; Imig, John D. // American Journal of Hypertension;Aug2014, Vol. 27 Issue 8, p1087 

    BACKGROUND Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, demonstrates antihypertensive and organ protective effects in hypertension. We investigated the efficacy of AZL-M to ameliorate metabolic syndrome and kidney damage associated with type 2 diabetes using Zucker diabetic...

  • ANGIOTENSIN II RECEPTOR ANTAGONISTS. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2009, p46 

    The article presents information on angiotensin II receptor antagonists, an antihypertensive agent, including dosage, usage, adverse reactions, side effects, precautions, and possible interaction with other drugs.

  • ANGIOTENSIN II RECEPTOR ANTAGONISTS.  // Davis's Drug Guide for Nurses, 9th edition;2005, p69 

    Presents clinical information on antihypertensive angiotensin II receptor antagonists. Pharmacokinetics; Adverse reactions and side effects of the drug; Drug interactions; Drug administration.

  • Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy. Scialom, Sophie; Malamut, Georgia; Meresse, Bertrand; Guegan, Nicolas; Brousse, Nicole; Verkarre, Virginie; Derrieux, Coralie; Macintyre, Elizabeth; Seksik, Philippe; Savoye, Guillaume; Cadiot, Guillaume; Vuitton, Lucine; Marthey, Lysiane; Carbonnel, Franck; Cerf-Bensussan, Nadine; Cellier, Christophe // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Background and Objectives: Anti-hypertensive treatment with the angiotensin II receptor antagonist olmesartan is a rare cause of severe Sprue-like enteropathy. To substantiate the hypothesis that olmesartan interferes with gut immune homeostasis, clinical, histopathological and immune features...

  • Increased reporting of adverse reactions to ACE inhibitors associated with limitations to drug reimbursement for angiotensin-II receptor antagonists. Cosentino, Marco; Leoni, Olivia; Michielotto, Donatella; Punginelli, Maurizia; Lecchini, Sergio; Frigo, Gianmario // European Journal of Clinical Pharmacology;Sep2001, Vol. 57 Issue 6/7, p509 

    Background and aim: From February 1998 to September 1999, the Italian Ministry of Health limited angiotensin-II type-1 (AT1) receptor antagonist reimbursement only to patients who necessitated discontinuation of angiotensin converting enzyme (ACE) inhibitor treatment due to cough or angioedema....

  • Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Hasford, Joerg; Schröder-Bernhardi, Detlef; Rottenkolber, Marietta; Kostev, Karel; Dietlein, Gerhard // European Journal of Clinical Pharmacology;Nov2007, Vol. 63 Issue 11, p1055 

    Effective treatment of hypertension requires continued prescribing of antihypertensive medications for many years. Persistence in prescribing habits, however, has been reported to be low. The study described herein – which is completely independent of pharmaceutical sponsors – was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics